AR016667A1 - Uso de una combinacion de un antiestrogeno mas progestina para la preparacion de un medicamento util para proveer la anticoncepcion y un kit deanticonceptivos adaptados para la administracion oral diaria - Google Patents
Uso de una combinacion de un antiestrogeno mas progestina para la preparacion de un medicamento util para proveer la anticoncepcion y un kit deanticonceptivos adaptados para la administracion oral diariaInfo
- Publication number
- AR016667A1 AR016667A1 ARP980105591A ARP980105591A AR016667A1 AR 016667 A1 AR016667 A1 AR 016667A1 AR P980105591 A ARP980105591 A AR P980105591A AR P980105591 A ARP980105591 A AR P980105591A AR 016667 A1 AR016667 A1 AR 016667A1
- Authority
- AR
- Argentina
- Prior art keywords
- antiestrogen
- combination
- preparation
- oral administration
- progestin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de una combinacion de un antiestrogeno más progestina para la preparacion de un medicamento util para proveer la anticoncepcion que comprende unacantidad efectiva anticonceptiva de una combinacion de un antiestrogeno de Formula (I) o (II) donde,R1 es H, Oh, carboalcoxi C2-12, alcoxi C1-12, halogenomono- o poli-fluoralcoxi C1-12; R2 es H, OH, carboalcoxi C2-12, alcoxi C1-12, halogeno mono- o poli-fluoralcoxi C1-12, ciano, alquilo C1-6 o trifluormetilo,siempre que cuando R1 es H, R2 no sea OH; R3 y R4 son cada uno independientemente, H, OH, carboalcoxi C2-12, alcoxi C1-12, halogeno mono- o poli-fluoralcoxiC1-12 o ciano, siempre que cuando R1 es H, R2 no sea OH; X es H, alquilo C1-6, ciano, nitro, trifluormetilo, o halogeno; n es 2 o 3; Yes un heterociclo de 5-7miembros, saturado, parcialmente saturado o insaturado que contiene un nitrogeno, que puede opcionalmente contener un segundo heteroátomo, seleccionado delgrupo formado por -O-, -NH-, alquilamina C1-6, -N=, y S(O)m; m es 0-2;o una sal farmacéuticamente aceptable del mismo, y una prostegina durante 28 díasconsecutivos por ciclo menstrual de 28 días. Además se describe un kit de anticonceptivos adaptados para la administracion oral diaria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96508397A | 1997-11-06 | 1997-11-06 | |
| PCT/US1998/023427 WO1999024027A2 (en) | 1997-11-06 | 1998-11-04 | Anti-estrogen plus progestin containing oral contraceptives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016667A1 true AR016667A1 (es) | 2001-07-25 |
Family
ID=25509417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105591A AR016667A1 (es) | 1997-11-06 | 1998-11-05 | Uso de una combinacion de un antiestrogeno mas progestina para la preparacion de un medicamento util para proveer la anticoncepcion y un kit deanticonceptivos adaptados para la administracion oral diaria |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1051179B1 (es) |
| JP (1) | JP2001522798A (es) |
| CN (1) | CN1278732A (es) |
| AR (1) | AR016667A1 (es) |
| AT (1) | ATE304359T1 (es) |
| AU (2) | AU760540B2 (es) |
| BG (1) | BG104451A (es) |
| BR (1) | BR9813982A (es) |
| CA (1) | CA2307210A1 (es) |
| CZ (1) | CZ294155B6 (es) |
| DE (1) | DE69831605T2 (es) |
| DK (1) | DK1051179T3 (es) |
| EA (1) | EA200000492A1 (es) |
| EE (1) | EE04092B1 (es) |
| ES (1) | ES2246541T3 (es) |
| GE (1) | GEP20043290B (es) |
| HR (1) | HRP20000269A2 (es) |
| HU (1) | HUP0100293A3 (es) |
| ID (1) | ID24568A (es) |
| IL (1) | IL135621A0 (es) |
| NO (1) | NO20002167L (es) |
| NZ (1) | NZ503890A (es) |
| PL (1) | PL340623A1 (es) |
| SK (1) | SK6482000A3 (es) |
| TR (1) | TR200001268T2 (es) |
| UA (1) | UA68365C2 (es) |
| WO (1) | WO1999024027A2 (es) |
| ZA (1) | ZA9810136B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL120263A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to prevent bone loss-progesterone and estrogen agonists |
| KR100620772B1 (ko) * | 1998-05-15 | 2006-09-13 | 와이어쓰 | 에스트로겐과 2-페닐-1-[4-(2-아미노에톡시)-벤질]-인돌을 포함하는 약제학적 조성물 |
| US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| US6380166B1 (en) | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| CN1196708C (zh) * | 1999-09-13 | 2005-04-13 | 惠氏公司 | 2－(4－羟基－苯基)－1－[4－(2－氨－1－基－乙氧基)－苄基]－1h－吲哚－5－酚的吡喃葡糖苷轭合物 |
| US6376486B1 (en) | 2000-07-06 | 2002-04-23 | American Home Products Corporation | Methods of inhibiting sphincter incontinence |
| HUP0401268A2 (hu) | 2001-07-31 | 2004-11-29 | Pfizer Products Inc. | Ösztrogén agonisták/antagonisták, ösztrogének és progesztinek kombinációját tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására |
| AU2005302706B2 (en) | 2004-10-27 | 2011-12-15 | Janssen Pharmaceutica N.V. | Indole derivatives useful as progesterone receptor modulators |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| UY29527A1 (es) * | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| DE102008057230A1 (de) * | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
| ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| UA122346C2 (uk) | 2015-10-01 | 2020-10-26 | Олема Фармасьютикалз, Інк. | ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ |
| WO2017100715A1 (en) | 2015-12-09 | 2017-06-15 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulator compounds |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CA3028751A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| NZ754865A (en) | 2017-01-06 | 2023-07-28 | G1 Therapeutics Inc | Combination therapy for the treatment of cancer |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| WO2019006393A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| TW202136265A (zh) | 2019-12-20 | 2021-10-01 | 美商Ｃ４醫藥公司 | 用於降解ｅｇｆｒ的異吲哚啉酮及吲唑化合物 |
| TW202146412A (zh) | 2020-03-05 | 2021-12-16 | 美商Ｃ４醫藥公司 | 用於標靶降解brd9之化合物 |
| WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA716118B (en) * | 1970-10-05 | 1972-05-31 | Richardson Merrell Inc | Contraception |
| ZA9510926B (en) * | 1994-12-23 | 1996-07-03 | Schering Ag | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| IL120263A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to prevent bone loss-progesterone and estrogen agonists |
| DE122009000061I1 (de) * | 1996-04-19 | 2009-12-31 | Wyeth N D Ges D Staates Delawa | Östrogene Verbindungen |
| US5747480A (en) * | 1996-05-08 | 1998-05-05 | American Home Products Corporation | Oral contraceptive |
-
1998
- 1998-04-11 ID IDW20000811A patent/ID24568A/id unknown
- 1998-04-11 UA UA2000063196A patent/UA68365C2/uk unknown
- 1998-11-04 SK SK648-2000A patent/SK6482000A3/sk unknown
- 1998-11-04 NZ NZ503890A patent/NZ503890A/xx unknown
- 1998-11-04 CA CA002307210A patent/CA2307210A1/en not_active Abandoned
- 1998-11-04 WO PCT/US1998/023427 patent/WO1999024027A2/en not_active Application Discontinuation
- 1998-11-04 JP JP2000520119A patent/JP2001522798A/ja not_active Ceased
- 1998-11-04 CZ CZ20001661A patent/CZ294155B6/cs not_active IP Right Cessation
- 1998-11-04 TR TR2000/01268T patent/TR200001268T2/xx unknown
- 1998-11-04 AU AU13031/99A patent/AU760540B2/en not_active Ceased
- 1998-11-04 DE DE69831605T patent/DE69831605T2/de not_active Expired - Lifetime
- 1998-11-04 ES ES98956525T patent/ES2246541T3/es not_active Expired - Lifetime
- 1998-11-04 CN CN98810911A patent/CN1278732A/zh active Pending
- 1998-11-04 BR BR9813982-7A patent/BR9813982A/pt not_active Application Discontinuation
- 1998-11-04 EP EP98956525A patent/EP1051179B1/en not_active Expired - Lifetime
- 1998-11-04 EE EEP200000211A patent/EE04092B1/xx not_active IP Right Cessation
- 1998-11-04 AT AT98956525T patent/ATE304359T1/de not_active IP Right Cessation
- 1998-11-04 HU HU0100293A patent/HUP0100293A3/hu unknown
- 1998-11-04 DK DK98956525T patent/DK1051179T3/da active
- 1998-11-04 GE GEAP19985364A patent/GEP20043290B/en unknown
- 1998-11-04 EA EA200000492A patent/EA200000492A1/ru unknown
- 1998-11-04 IL IL13562198A patent/IL135621A0/xx unknown
- 1998-11-04 PL PL98340623A patent/PL340623A1/xx unknown
- 1998-11-05 AR ARP980105591A patent/AR016667A1/es not_active Application Discontinuation
- 1998-11-05 ZA ZA9810136A patent/ZA9810136B/xx unknown
-
2000
- 2000-04-27 NO NO20002167A patent/NO20002167L/no not_active Application Discontinuation
- 2000-05-05 HR HR20000269A patent/HRP20000269A2/hr not_active Application Discontinuation
- 2000-05-17 BG BG104451A patent/BG104451A/xx unknown
-
2003
- 2003-06-23 AU AU2003204896A patent/AU2003204896B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016667A1 (es) | Uso de una combinacion de un antiestrogeno mas progestina para la preparacion de un medicamento util para proveer la anticoncepcion y un kit deanticonceptivos adaptados para la administracion oral diaria | |
| NO963053L (no) | Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav | |
| BR0111358A (pt) | Compostos de tioacetamida e seu uso | |
| IL57648A (en) | 2-substituted-5,9-dimethyl-2'-hydroxy-6,7-benzomorphanes,their preparation and pharmaceutical compositions containing them | |
| CA2136404A1 (fr) | Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale | |
| ZA806519B (en) | Secondary amines,their preparation and use in pharmaceutical compositions | |
| ES8202808A1 (es) | Un procedimiento para la preparacion de derivados de benzofurano. | |
| KR830002510A (ko) | 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물 | |
| ZA922910B (en) | Heterocylic pharmaceutical compounds preparation and use | |
| ES475533A1 (es) | Un metodo para la preparacion de formas racemicas y optica- mente activas de 2-(4-difenilil)-n-(dimetilamino-alquil)pro-pionamida | |
| ATE2954T1 (de) | Tetrahydropyridinyl-indol-derivate und ihre salze, ihre herstellung, ihre anwendung als arzneimittel und sie enthaltende zusammensetzungen. | |
| ATE110568T1 (de) | Pharmazeutisches präparat zur behandlung des katarakts. | |
| NO176018C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive S-enantiomerer av substituerte 2-aminotetraliner | |
| JPS6470412A (en) | Medicinal composition | |
| ZA922625B (en) | Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients | |
| AP9801235A0 (en) | Erythromycin derivatives. | |
| CA2228524A1 (en) | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies | |
| KR980002033A (ko) | 트리아졸 유도체 또는 그 염 | |
| GB2085437B (en) | Propanolamine derivatives | |
| IL89185A0 (en) | Basic-substituted 5-halo-thieno-sothiazol-3-(2h)-one 1,1-dioxides,their preparation and pharmaceutical compositions containing them | |
| NO950177L (no) | Farmakologisk aktive erivater | |
| TR200000154T2 (tr) | 2,4,4-Trisübstitüe-1,3-Dioksolan mantar önleyiciler. | |
| BE896635A (fr) | Compositions pharmaceutiques analgesiques contenant des 5-phenyl-1,4-benzodiazepines. | |
| CO5280093A1 (es) | Metodos de tratamiento | |
| KR920019349A (ko) | 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |